Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial

NCT04046822 is registered in ClinicalTrials.gov with Federico II University as lead sponsor.

NCT NCT04046822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04046822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial
Lead sponsor
Federico II University
Phase
Phase 4
Overall status
Unknown status
Start date
January 9, 2019
Completion date
April 30, 2020
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microbiome, obesity, weight loss